Special Protocol Assessment Requests Up 10%-15% Over FY2002
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sponsor requests for special protocol assessments continue to rise with a 10% to 15% increase so far in 2003, according to FDA.
You may also be interested in...
FDA Special Protocol Assessments Illuminate Evolution Of Cancer Endpoints
FDA’s special protocol assessment process is being used overwhelmingly for cancer programs, with more than half of pivotal trial SPAs going to oncologics.
Encysive Thelin pivotal trial
Encysive plans to submit an NDA for Thelin (sitaxsentan) for pulmonary arterial hypertension "on or around the end of the first quarter in 2005." The company, formerly Texas Biotech, announced enrollment was complete for the Phase III Sitaxsentan To Relieve ImpaireD Exercise (STRIDE-2) study Sept. 8. The 240-patient, 18-week, double-blind, placebo-controlled trial includes a "third party bosentan [Actelion's Tracleer] arm," Encysive says. Topline data are expected in February 2005. The confirmatory trial is being conducted under FDA's special protocol assessment program (1Pharmaceutical Approvals Monthly Sept. 1, 2003, p. 17)...
Cellegy Cellegesic SPA Clears FDA; NDA Resubmission Planned For Q3 2004
Cellegy’s Special Protocol Assessment agreement with FDA for its anal fissure therapy Cellegesic allows the firm to use pain at three weeks as the primary endpoint for a confirmatory trial.